Loading...
•
Jun 30, 2025
Axogen Q2 2025 Earnings Report
Axogen reported strong financial results for the second quarter of 2025, with significant revenue growth and a return to net income.
Key Takeaways
Axogen, Inc. delivered a robust second quarter in 2025, achieving $56.7 million in revenue, an 18.3% increase year-over-year. The company reported a net income of $0.6 million, a significant improvement from a net loss in the prior year, and saw strong growth in adjusted EBITDA and gross margin.
Second quarter revenue reached $56.7 million, marking an 18.3% increase compared to the same period in 2024.
The company achieved a net income of $0.6 million ($0.01 per share), a positive shift from a net loss of $1.9 million in Q2 2024.
Adjusted EBITDA significantly increased to $9.3 million, up from $5.6 million in the second quarter of 2024.
Gross margin improved to 74.2% in Q2 2025, compared to 73.8% in Q2 2024.
Forward Guidance
Axogen has raised its full-year revenue guidance to at least 17% growth, or $219 million, and expects gross margin to be between 73% and 75%. The company also reiterates its expectation to be net cash flow positive for the full year.
Positive Outlook
- Raised full-year revenue guidance to at least 17% growth, targeting $219 million.
- Anticipated gross margin for the full year is expected to be in the range of 73% to 75%.
- Expectation to be net cash flow positive for the full year.
- FDA accepted the BLA filing for Avance® Nerve Graft with a PDUFA goal date of September 5, 2025.
- Completed key regulatory milestones for Avance® Nerve Graft approval, including late-cycle meeting, pre-licensing inspection, and sponsor inspection.
Challenges Ahead
- Gross margin for the year is expected to be negatively impacted by approximately 1% due to one-time costs related to the anticipated Avance® Nerve Graft BLA approval.
- No other specific negative forward guidance points were explicitly stated in the report beyond the gross margin impact.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...